NMTC
NeuroOne Medical Technologies Corporation NASDAQ Listed Mar 15, 2018$1.12
+13.69%
vs $0.99
Mkt Cap $9.7M
52w Low $0.96
2.6% of range
52w High $6.96
50d MA $1.64
200d MA $3.60
P/E (TTM)
—
EV/EBITDA
—
P/B
1.1x
Debt/Equity
0.0x
ROE
-106.7%
P/FCF
-2.6x
RSI (14)
28.20
ATR (14)
$0.11
Beta
0.58
50d MA
$1.64
200d MA
$3.60
Avg Volume
599.9K
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
7599 Anagram Drive · Eden Prairie, MN 55344 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | BMO | -0.58 | -0.28 | +52.0% | 1.52 | +0.0% | +20.4% | +6.0% | -3.1% | +0.0% | +16.0% | — |
| May 12, 2026 | BMO | -0.23 | -0.25 | -10.3% | 4.33 | -1.2% | +1.4% | +2.7% | +2.0% | -8.5% | +7.6% | — |
| Feb 17, 2026 | BMO | -0.24 | -0.18 | +25.0% | 4.07 | +2.9% | +0.2% | +4.2% | -4.0% | +0.0% | +2.5% | — |
| Dec 17, 2025 | BMO | -0.04 | -0.05 | -25.0% | 4.01 | +0.0% | +7.2% | +2.6% | +9.3% | -10.8% | +6.7% | — |
| Aug 14, 2025 | BMO | -0.05 | -0.03 | +40.0% | 4.98 | -1.0% | -1.2% | +1.2% | -2.6% | -7.0% | +2.4% | — |
| May 13, 2025 | BMO | -0.09 | -0.07 | +22.2% | 3.86 | +1.0% | +2.6% | -0.5% | +1.3% | -0.5% | -6.0% | — |
| Feb 12, 2025 | BMO | -0.10 | 0.06 | +160.0% | 6.72 | +6.2% | +1.8% | +5.3% | -3.3% | +0.0% | -3.4% | — |
| Dec 17, 2024 | BMO | -0.09 | -0.11 | -22.2% | 4.74 | +3.6% | -6.3% | +2.5% | +0.0% | -2.2% | +3.8% | — |
| Aug 14, 2024 | BMO | -0.09 | -0.10 | -11.1% | 4.45 | -2.9% | -1.6% | +0.0% | +9.6% | +3.1% | -5.9% | — |
| May 14, 2024 | BMO | -0.09 | -0.11 | -22.2% | 6.84 | -2.6% | -7.0% | -0.9% | +2.9% | -2.8% | -1.0% | — |
| Feb 13, 2024 | BMO | -0.14 | -0.14 | +0.0% | 8.46 | -0.7% | -23.4% | -2.8% | -1.9% | +6.8% | +0.9% | — |
| Dec 14, 2023 | BMO | -0.17 | -0.13 | +25.7% | 10.32 | +0.0% | -11.0% | -11.1% | +2.9% | -1.4% | +0.7% | — |
| Aug 14, 2023 | AMC | -0.20 | -0.20 | +2.4% | 6.54 | +0.0% | -3.7% | -3.8% | +1.0% | -1.0% | +2.0% | — |
| May 11, 2023 | AMC | -0.20 | -0.21 | -2.4% | 7.80 | +3.8% | +0.8% | +9.2% | -9.8% | +0.8% | -5.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 15 | Alliance Global Partners | Maintains | Buy → Buy | — | $6.54 | $6.54 | +0.0% | -3.7% | -3.8% | +1.0% | -1.0% | +2.0% |
| Mar 28 | Craig-Hallum | Downgrade | Buy → Hold | — | $13.32 | $10.50 | -21.2% | -46.8% | -0.8% | -4.3% | -1.8% | -1.8% |
| Dec 3 | Alliance Global Partners | Maintains | Buy → Buy | — | $12.54 | $12.90 | +2.9% | -1.9% | +10.2% | +6.2% | +5.0% | +3.2% |
| Nov 15 | Craig-Hallum | Maintains | Buy → Buy | — | $16.50 | $17.04 | +3.3% | -2.5% | -1.9% | -3.0% | -3.1% | -1.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Wambeke David J.Off | Chief Business Officer | Buy | 33,333 | $2.01 | $67K | 199,999 | -1.78% | -2.67% |
| Jun 30, 2026 | Christianson MarkOff | Market Development Director | Sell | 10,000 | $3.18 | $32K | 20,692 | +3.00% | +4.73% |
8-K · 8.01
!! High
NeuroOne Medical Technologies Corporation -- 8-K 8.01: Material Event / Announcement
Aug 27
8-K · 2.02
!! High
NeuroOne Medical Technologies Corporation -- 8-K 2.02: Earnings Results
Aug 13
8-K · 7.01
! Medium
NeuroOne Medical Technologies Corporation -- 8-K 7.01: Regulation FD Disclosure
May 22
8-K · 2.02
!! High
NeuroOne Medical Technologies Corporation -- 8-K 2.02: Earnings Results
May 12
8-K · 8.01
!! High
NeuroOne Medical Technologies Corporation -- 8-K 8.01: Material Event / Announcement
NeuroOne Medical Technologies regained Nasdaq compliance after its stock price recovered to $1.00 or above for ten consecutive trading days, resolving its prior listing deficiency notice.
May 4
8-K · 5.02
!!! Very High
NeuroOne Medical Technologies Corporation -- 8-K 5.02: Executive Change
NeuroOne Medical Technologies' CFO Ronald McClurg will retire June 30, 2026, creating potential leadership uncertainty during a critical financial oversight period.
Apr 30
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
NMTC executed a stock split with proportional adjustments to equity plans and outstanding options, potentially signaling management confidence but diluting per-share metrics that investors should recalibrate.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
NMTC amended its 2025 equity plan without shareholder approval, potentially diluting shares and increasing management compensation flexibility, which could pressure stock performance if excessive.
Apr 3
8-K · 8.01
!! High
NeuroOne Medical Technologies Corporation -- 8-K 8.01: Material Event / Announcement
NeuroOne Medical Technologies set its 2026 annual shareholder meeting for April 3, 2026, with additional details forthcoming in the proxy statement.
Feb 25
8-K
NeuroOne Medical Technologies Corporation -- 8-K Filing
NeuroOne Medical Technologies reported Q1 FY2026 financial results and business updates, though specific metrics and outcomes require review of the complete filing for investor impact assessment.
Feb 17
Institutional (13F) — Top 9
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 352,774 | $1M | New | Jun 2026 |
| 2 | Bard Associates Inc | 305,428 | $929K | New | Jun 2026 |
| 3 | Perkins Capital Management Inc | 244,656 | $744K | New | Jun 2026 |
| 4 | Renaissance Technologies Llc | 70,861 | $215K | New | Jun 2026 |
| 5 | Cambridge Investment Research Advisors, Inc. | 56,998 | $174K | New | Jun 2026 |
| 6 | Citadel Advisors Llc | 30,064 | $91K | New | Jun 2026 |
| 7 | Blackrock, Inc. | 25,121 | $76K | New | Jun 2026 |
| 8 | Belpointe Asset Management Llc | 12,500 | $38K | New | Jun 2026 |
| 9 | Sbi Securities Co., Ltd. | 13 | $40 | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Total Market Index Fund | 13,914 | $49K | May 2026 |
| 2 | Fidelity Series Total Market Index Fund | 11,879 | $42K | May 2026 |
Valuation
Market Cap
$9.7M
Enterprise Value
$925K
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.12x
P/B
1.06x
P/S
0.97x
P/FCF
-2.57x
EV/EBITDA
—
Shares Out
6.7M
Financials (TTM)
Revenue
$10.0M
Net Income
-$7.1M
EBITDA
-$6.9M
Free Cash Flow
-$2.9M
Op Cash Flow
-$3.1M
EPS Basic
$-0.54
EPS Diluted
$-0.91
EPS Forward
$-0.74
Gross Margin
55.7%
Op Margin
-76.0%
Net Margin
-71.5%
Balance Sheet
Total Assets
$10.8M
Total Liab.
$3.7M
Total Equity
$7.1M
Cash
$6.6M
LT Debt
$0
Book Value/Sh
$1.06
Debt/Equity
0.04x
Current Ratio
4.44
Quick Ratio
3.47
Returns & Growth
ROE
-106.7%
ROA
-79.6%
ROIC
-49.1%
Rev Growth YoY
+250.3%
EPS Growth YoY
+80.4%
Price Returns
2W
-19.4%
1M
-32.5%
3M
-63.8%
6M
-77.5%
12M
-79.9%
Technicals
52W High
$6.96
52W Low
$0.96
50d MA
$1.64
200d MA
$3.60
RSI (14)
28.20
ATR (14)
$0.11
Beta
0.58
Avg Volume
600K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.00
High
$3.00
Low
$3.00
Median
$3.00
Data updated apr 26, 2026 3:21pm
· Source: financialmodelingprep.com